NEW YORK, March 5 - Orchid BioSciences and First Genetic Trust on Tuesday said they plan to co-develop and market a range of pharmacogenetic services to the private sector, academia, and health-care providers.

The alliance hopes to provide researchers the tools to asses the correlates between genotypes and phenotypes. Specifically, it seeks to generate patient registries and support clinical trials, develop and validate assays, and provide genotyping services, bioinformatics, and data management.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.